Assignee
PHENEX PHARMACEUTICALS AG
DE·7 granted patents·5 pending applications·41 citations·filing 2002–2021
Top patents by PatentIndex Score
12 records- 0187US7098336B2FXR NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Aug 29, 2006·18 cites·13 claims
- 0282US7034046B2NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Apr 25, 2006·19 cites·7 claims
- 0378US10981908B2Aryl hydrocarbon receptor (AHR) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Granted Apr 20, 2021·1 cites·18 claims
- 0471US9458104B2Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγPHENEX PHARMACEUTICALS AG·Filed 2013·Granted Oct 4, 2016·2 cites·23 claims
- 0566US9815851B2Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseasesPHENEX PHARMACEUTICALS AG·Filed 2012·Granted Nov 14, 2017·1 cites·22 claims
- 0653US2023108408A1Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)PHENEX PHARMACEUTICALS AG·Filed 2021·Application pending·0 cites
- 0748US11376241B2Aryl hydrocarbon receptor (AhR) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Granted Jul 5, 2022·0 cites·14 claims
- 0846US2010184809A1Heterocyclic FXR Binding CompoundsPHENEX PHARMACEUTICALS AG·Filed 2007·Application pending·0 cites
- 0945US2011263046A1Methods of identification of novel ligands for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (NR1F3) activityPHENEX PHARMACEUTICALS AG·Filed 2009·Application pending·0 cites
- 1042US10301272B2Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]PHENEX PHARMACEUTICALS AG·Filed 2013·Granted May 28, 2019·0 cites·30 claims
- 1142US2021323995A1Isolithocholic acid or isoallolithocholic acid and deuterated derivatives thereof for preventing and treating clostridium difficile-associated diseasesPHENEX PHARMACEUTICALS AG·Filed 2019·Application pending·0 cites
- 1239US2020031805A1Aryl hydrocarbon receptor (ahr) modulator compoundsPHENEX PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →